RecruitingPhase 1NCT07401875

A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)

Studying Hereditary clear cell renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Eric Jonasch, MD, MD
M.D. Anderson Cancer Center
Intervention
Nivolumab(drug)
Enrollment
35 enrolled
Eligibility
18 years · All sexes
Timeline
20262029

Study locations (1)

Collaborators

HiberCell, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07401875 on ClinicalTrials.gov

Other trials for Hereditary clear cell renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Hereditary clear cell renal cell carcinoma

← Back to all trials